Gilead Sciences has launched Viread.com, a new site that provides information about the company’s HIV drug Viread, recently approved by the FDA for the treatment of HIV.
Designed as a comprehensive resource, the site provides user-friendly clinical and educational information, as well as links to other HIV/AIDS Internet sites.
Viread (tenofovir disoproxil fumarate) is the first nucleotide analogue reverse transcriptase inhibitor (NtRTI) approved for the treatment of HIV in the US and Europe. The drug works by blocking reverse transcriptase, an enzyme involved in the replication of HIV.
As a nucleotide, Viread remains in cells for longer periods of time than many other antiretroviral drugs, allowing for once-daily dosing. The approved dosing of Viread is one 300mg tablet taken once daily with a meal. In the US, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.